Switzerland· 66738001
Alunbrig
A brigatinib product containing brigatinibum, registered in Switzerland and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 13 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Brigatinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01ED04 (brigatinib), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 8 of them publish a price we can compare per daily dose
Brigatinib · ATC L01ED04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of brigatinib costs, country by country.
Normalised to the WHO defined daily dose (0.18 g), the median price runs from $16.82 in Czechia to $204.41 in Switzerland — a ×12 gap.
- Switzerland: $204.41 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Brigatinib · price per daily dose (0.18 g)
USD · FX 28 Sept 2026
- CH Switzerland$204.41
- FR France$112.63
- CZ Czechia$16.82
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- brigatinibum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L01ED04
- ATC class
- Brigatinib
- Defined daily dose
- 0.18 g, O
- Swissmedic category
- A
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680667380016Blist 28 StkCHF 802.05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
576 interactions on record for brigatinib.
Graded by severity as the source publishes them — 126 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Brigatinib · interactions on record
576 records
- 126 severe
- 442 moderate
- 8 minor
Most severe, free to view
- AprepitantA04AD12severe
- LonafarnibA16AX20severe
- VoxelotorB06AX03severe
- DronedaroneC01BD07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Brigatinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaALUNBRIGTakeda Pharma A/S, Vallensbaek Strand
- FinlandAlunbrigTakeda Pharma A/S
- FranceALUNBRIG 30 mg, comprimé pelliculéTAKEDA PHARMA (DANEMARK)
- IrelandAlunbrig 30 mg film-coated tabletsTakeda Pharma A/S
- IcelandAlunbrigTakeda Pharma A/S
- NetherlandsAlunbrig 30 mg, filmomhulde tabletAriad Pharma Ltd
- NorwayAlunbrigTakeda Pharma A/S (1)
- PolandAlunbrigTakeda Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Alunbrig
- Liechtenstein · Alunbrig
- Norway · Alunbrig
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c629ed3a-2fa5-4693-9a30-792d10ac43bf GET /v1/drugs/c629ed3a-2fa5-4693-9a30-792d10ac43bf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "brigatinibum 30 mg",
"valid_from": "2024-12-01",
"limitations": "[{\"description\":\"Erstlinientherapie (ohne Preismodell)<br>\\nNach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes. Zur Behandlung von erwachsenen Patienten mit lokal fortgeschrittenem oder metastasiertem ALK (Anaplastic-lymphoma-kinase)-positivem nicht-kleinzelligem Lungenkarzinom (NSCLC), die nicht mit einem ALK-Inhibitor vorbehandelt sind, als Monotherapie. Im Falle einer Progression ist die Behandlung abzubrechen.<br> \\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21205.01<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"21205.01\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2024-12-01\",\"validTo\":\"2027-11-30\"},{\"description\":\"Spätere Therapielinie (mit Preismodell)<br>\\nNach Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes. Zur Behandlung von erwachsenen Patienten mit metastasiertem ALK (Anaplastic-lymphoma-kinase)-positivem nicht-kleinzelligem Lungenkarzinom (NSCLC) als Monotherapie nach Progression unter vorangegangener Behandlung mit Crizotinib. Im Falle einer Progression ist die Behandlung abzubrechen.<br>\\nDie Takeda Pharma AG vergütet im Rahmen des post-Crizotinib Einsatzes von ALUNBRIG dem Krankenversicherer, bei dem die versicherte Person zum Zeitpunkt des Bezugs versichert war, auf dessen Aufforderung hin für jede bezogene Packung ALUNBRIG 3.70 % des Fabrikabgabepreises zurück.<br>\\nDie Mehrwertsteuer kann nicht zusätzlich zu den Rückvergütungsbeträgen zurückgefordert werden. Die Aufforderung zur Rückerstattung soll ab dem Zeitpunkt der Verabreichung erfolgen.<br>\\nFolgender Code ist an den Krankenversicherer zu übermitteln: 21205.02<br>\\n<br>\",\"costApproval\":null,\"indication\":\"21205.02\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2024-12-01\",\"validTo\":\"2027-11-30\"}]",
"galenic_form": "Filmtabl 30 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2021-12-01",
"self_retention_pct": 10
}See everything about brigatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.